EU Marketing Approval In Sight For 11 Drugs After CHMP OK; Thumbs Down For Two

The European Medicines Agency’s key scientific committee, the CHMP, has recommended for approval throughout Europe a total of 11 new drugs. Two medicines received a negative opinion from the committee and the marketing authorization application for one product has been withdrawn. A further eight products are set to receive indication extensions. The medicines that got positive opinions are likely to secure official approval within the next few months.

Approve
EU approval is in sight for drugs cleared by CHMP • Source: Shutterstock

The eleven products that the European Medicines Agency’s key scientific committee, the CHMP, this week recommended for approval throughout Europe include five with orphan status and three generics. Of the 13 products the CHMP assessed for an opinion during its four-day meeting (Also see "EU CHMP Decides On New Oncology Drugs & New Treatments for Mastocytosis, Atopic Dermatitis" - Pink Sheet, 19 July, 2017.), two got the thumbs down. Eight products will have their current indications extended and one company has withdrawn the marketing application for one of its products.

The drugs that got positive opinions from the CHMP and that are now set for formal EU approval include the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>